BioMarin Pharmaceutical Inc (BMRN)

Etorro trading 970x250
BioMarin Pharmaceutical Inc (BMRN) Logo

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California. Address: 770 Lindaro Street, San Rafael, CA, United States, 94901

BioMarin Pharmaceutical Inc News and around…

Latest news about BioMarin Pharmaceutical Inc (BMRN) common stock and company :

BIOMARIN PHARMACEUTICAL INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioMarin Pharmaceutical Inc.
27 Oct, 2021 Yahoo! Finance

Lead Plaintiff Deadline is December 22, 2021NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) in the United States District Court for the Northern District of California, on behalf of a class consisting of all persons and entities that purchased or otherwise acquired BioMarin securities between January 13, 20

BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
27 Oct, 2021 Yahoo! Finance

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

SHAREHOLDER ALERT: INNV HEPS BMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
27 Oct, 2021 FinancialContent
BMRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021
27 Oct, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ:BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin between January 13, 2020 and September 3, 2021, inclusive (the "Class Period").

CLASS ACTION UPDATE for EAR, NNOX and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
27 Oct, 2021 FinancialContent
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact
27 Oct, 2021 FinancialContent

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
27 Oct, 2021 Yahoo! Finance

LOS ANGELES, October 27, 2021--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc.

10 Healthcare and Software Stocks to Buy According to Michel Massoud’s Melqart Asset Management
27 Oct, 2021 Yahoo! Finance

In this article, we take a look at the 10 healthcare and software stocks to buy according to Michel Massoud’s Melqart Asset Management. If you want to skip our discussion of Melqart Asset Management’s history, investment philosophy, and hedge fund preference, go directly to 5 Healthcare and Software Stocks to Buy According to Michel Massoud’s Melqart […]

LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims
27 Oct, 2021 FinancialContent
BMRN DEADLINE: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
27 Oct, 2021 Yahoo! Finance

Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, inclusive (the "Class Period") have until December 21, 2021 to seek appointment as lead plaintiff in the BioMarin class action lawsuit. Commenced on October 22, 2021 in the Northern District of California, the BioMarin class action lawsuit (Berlinger v. BioMarin Pharmaceutical Inc., No. 21-cv-08254) charges BioMarin as well as certai

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2021 - BMRN
26 Oct, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - October 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get ...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
26 Oct, 2021 FinancialContent

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
26 Oct, 2021 Yahoo! Finance

LOS ANGELES, October 26, 2021--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc.

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BMRN
26 Oct, 2021 Yahoo! Finance

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 22, 2021.

CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
26 Oct, 2021 FinancialContent
BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
26 Oct, 2021 FinancialContent

The suit alleges defendants issued false statements concerning BioMarin business and prospects, resulting in its stock trading at inflated prices.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN
26 Oct, 2021 FinancialContent
BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: December 21, 2021
26 Oct, 2021 Yahoo! Finance

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired BioMarin between January 13, 2020 and September 3, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/bmrn.

SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
26 Oct, 2021 FinancialContent
/C O R R E C T I O N -- Pomerantz LLP/
26 Oct, 2021 Yahoo! Finance

Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities between January 13, 2020 and September 3, 2021,

Lawsuits Filed Against HYZN, NNOX and BMRN - Jakubowitz Law Pursues Shareholders Claims
25 Oct, 2021 FinancialContent
BIOMARIN PHARMACEUTICAL INC. (NASDAQ: BMRN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceutical Inc.
25 Oct, 2021 Yahoo! Finance

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) from January 13, 2020 through September 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Act of 1934.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
25 Oct, 2021 FinancialContent

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 21, 2021.

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct, 2021 FinancialContent

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma ...

2 Upcoming FDA Approval Decisions That Investors Should Really Watch
23 Oct, 2021 FinancialContent

The FDA is scheduled to announce these two key approval decisions in late November.

The Smartest Stocks to Buy With $250 Right Now
22 Oct, 2021 FinancialContent

A small amount of money can go a long way when you own high-quality companies.

Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
16 Oct, 2021 FinancialContent

This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other ...

NASDAQ:BMRN Investor Notice: Investigation over Possible Securities Laws Violations by BioMarin Pharmaceutical Inc.
22 Sep, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 09/22/2021 -- BioMarin Pharmaceutical Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Interesting BMRN Put And Call Options For January 2024
14 Sep, 2021 FinancialContent

Investors in BioMarin Pharmaceutical Inc (BMRN) saw new options become available this week, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
09 Sep, 2021 FinancialContent

Stifelhas upgradedBioMarin Pharmaceutical Inc's(NASDAQ: BMRN) to Buy from Hold with a price target of $96, up ...

BioMarin Pharmaceutical Inc (BMRN) is a NASDAQ Common Stock listed in , ,

970x250